Article

SARS-CoV-2 infection among patients with multiple sclerosis; A cross-sectional study

2020-10-20

Abstract excerpt

<h4>Background</h4> Neurological disability associated with multiple sclerosis and immunosuppressive or immunomodulatory therapy which is administered for it may increases the risk of SARS-CoV-2 infection and its morbidity/mortality. <h4>Objective</h4> In this study, we evaluated the infection rate and the severity of SARS-CoV-2 infection in patients with multiple sclerosis (MS) <h4>Methods</h4> One thousand and t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7c242406-af71-53fd-8c28-c63a08a3a910
DOI: 10.1101/2020.10.17.20214429

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

SARS-CoV-2 infection among patients with multiple sclerosis; A cross-sectional studyDOI 10.1101/2020.10.17.20214429Read

COVID-19 in Multiple Sclerosis Patients and Risk Factors for Severe InfectionSemantic proximity Read

Impact of mass vaccination on SARS-CoV-2 infections among the total multiple sclerosis population receiving immunomodulatory disease-modifying therapies in EnglandSemantic proximity Read

Disease Modifying Therapies and COVID-19 Severity in Multiple SclerosisSemantic proximity Read

Associations of DMT therapies with COVID-19 severity in multiple sclerosisSemantic proximity Read

Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.Semantic proximity Read

Associations of DMT Therapies with COVID-19 Severity in Multiple Sclerosis: An International Cohort StudySemantic proximity Read

COVID-19 Severity in Multiple Sclerosis: Putting Data Into ContextSemantic proximity Read

COVID-19 in multiple sclerosis patients and risk factors for severe infection.Semantic proximity Read

Multiple sclerosis and neuromyelitis optica spectrum disorders in Argentina: comparing baseline data from the Argentinean MS Registry (RelevarEM).Semantic proximity Read

COVID-19 OUTCOMES IN MS: EARLY EXPERIENCE FROM NYU MULTIPLE SCLEROSIS COMPREHENSIVE CARE CENTERSemantic proximity Read

Impact of the first COVID-19 pandemic wave on the Scottish Multiple Sclerosis Register populationSemantic proximity Read

Increased Rate of Hospitalisation for COVID-19 Amongst Rituximab Treated Multiple Sclerosis Patients: A Study of the Swedish MS RegistrySemantic proximity Read